Valeant Pharmaceuticals reported $378M in EBIT for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Amgen AMGN:US USD 2.66B 71M
Ani Pharmaceuticals ANIP:US USD -3454000 6.78M
Aurora Cannabis Inc ACB:CN CAD -73026000 13.79M
Biogen BIIB:US USD 872.1M 68.8M
Bristol Myers Squibb BMY:US USD 2.74B 461M
Canopy Growth Corp WEED:CN CAD -117273000 11.22M
Catalent CTLT:US USD 62M 199M
Corcept Therapeutics CORT:US USD 31.93M 502K
Danaher DHR:US USD 2.02B 190M
Eli Lilly And LLY:US USD 1.95B 294.9M
Endo International Ordinary Shares ENDP:US USD 55.64M 26.07M
Gilead Sciences GILD:US USD 2.81B 784M
Horizon Pharma HZNP:US USD 188.16M 41.16M
Lannett LCI:US USD -11277000 12.66M
Nektar Therapeutics NKTR:US USD -37471000 10.24M
Pacira Pharmaceuticals PCRX:US USD 21.78M 8.6M
Perrigo Ordinary Shares PRGO:US USD 52.2M 49.6M
Prestige Brands PBH:US USD 84.38M 2.63M
Revance Therapeutics RVNC:US USD -77484000 19.64M
Valeant Pharmaceuticals VRX:CN USD 378M 92M
Vertex Pharmaceuticals VRTX:US USD 1.13B 7.4M
Zoetis ZTS:US USD 725M 12M